Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy.
Sánchez
V
V
Heart Failure and Transplantation Program, Hospital 12 de Octubre, Madrid, Spain.
Delgado
J F
JF
Blasco
T
T
Dalmau
R
R
Morales
J M
JM
Escribano
P
P
Tello
R
R
Hernández
J
J
Velázquez
T
T
Sotelo
T
T
Gómez-Sánchez
M A
MA
Sáenz de la Calzada
C
C
D001379:Azathioprine / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000601:surgery; D003327:Coronary Disease / Q000601:surgery; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D008775:Methylprednisolone